Medical Therapy for Advanced Pancreatic Cancer: Work in Progress
DOI:
https://doi.org/10.6092/1590-8577/3393Keywords:
Acidosis, Lactic, Drug Resistance, Neoplasm, Pancreatic Neoplasms, Pathology, Clinical, Renin-Angiotensin System, TherapeuticsDownloads
References
Kang SP, Saif MW. Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP. J Pancreas (Online) 2008; 9:251-66. [PMID 18469437]
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324:1457-61. [PMID 19460966]
Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009; 16:259-66. [PMID 19732725]
Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors. Cancer Res 1989; 49:6449-65. [PMID 2684393]
Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997; 3:177-82. [PMID 9018236]
Warburg O. On the origin of cancer cells. Science 1956; 123:309-314. [PMID 13298683]
Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis 2008; 29:1675-84. [PMID 18632755]
Khakoo AY, Sidman RL, Pasqualini R, Arap W. Does the rennin angiotensin system participate in regulation of human vasculogenesis and angiogenesis? Cancer Res 2008; 68:9112-5. [PMID 19010879]
Noguchi R, Yoshiji H, Ikenaka Y, Namisaki T, Kitade M, Kaji K, et al. Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via antiangiogenic activities. Oncol Rep 2009; 22:355-60. [PMID 19578777]
Amaya K, Ohta T, Kitagawa H, Kayahara M, Takamura H, Fujimura T, et al. Angiotensin II activates MAP kinase and NF-kappaB through angiotensin II type I receptor in human pancreatic cancer cells. Int J Oncol 2004; 25:849-6. [PMID 15375532]
Gong Q, Davis M, Chipitsyna G, Yeo CJ, Arafat HA. Blocking angiotensin II type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells. Pancreas 2010; 39:581-94. [PMID 20118823]
Pezzilli R, Corinaldesi R, Morselli-Labate A. Pancreatic cancer and cancer screening programs: from nihilism to hope. JOP. J Pancreas (Online) 2010; 11:654-5. [PMID 21068511]
Singh S, Srivastava SK, Bhardwaj A, Owen LB, Singh AP. CXCL12-CXCR4 signaling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. British J Cancer 2010; 103:1671-9. [PMID 21045835]
Fukamachi T, Chiba Y, Wanga X, Saito H, Tagawa M, Kobayashi H. Tumor specific low pH environments enhance the cytotoxicity of lovastatin and cantharidin. Cancer Lett 2010; 297:182-9. [PMID 20831979]
Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. British J Cancer 2010; 103:1644-8. [PMID 20978506]
